Navigation Links
Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
Date:8/19/2007

- Planning for Phase 3 Trial Initiation on Track -

BRISBANE, Australia, Aug. 16 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced it has executed an agreement with Quintiles, the world's largest Contract Research Organisation, to utilise their services for a number of clinical development- related projects. This agreement includes the execution of the Phase 3 clinical trial of anti-cancer drug PI-88 for the treatment of primary liver cancer (hepatocellular carcinoma).

Progen remains on track to initiate recruitment for the Phase 3 clinical trial in the fourth quarter of 2007. Quintiles operates directly in each of the 14 North American, European and Asian countries where Progen will be conducting the Phase 3 PI-88 trial.

"Quintiles has over 18,000 employees world-wide and has managed over 520 separate oncology studies. A number of these employees have been working with us as we prepare to initiate our Phase 3 trial in post-resection liver cancer. We have been consistently impressed with Quintiles's infrastructure in the regions where the trial will be conducted. They have already demonstrated to us that they have the communication and project management systems in place to successfully integrate key clinical operational procedures on the international level that this important trial requires," said Justus Homburg, Progen's CEO.

"Since the middle of last year, we have been working with external advisors, including Quintiles and the U.S. Food and Drug Administration (FDA), to develop our Phase 3 trial. We are aggressively pursuing the launch of this clinical trial on schedule and in parallel continue our discussions with the FDA on the SPA process," concluded Mr. Homburg.

The primary endpoint of the Phase 3 trial is the length of time patients remain disease-free (disease free survival or DFS) following surgery to remove tumour-affected parts of the liver. "Recent feedback f
'/>"/>

SOURCE Progen Pharmaceuticals Limited

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
3. Progens Phase 2 Liver Cancer Trial Exceeds Efficacy Objective
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
7. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  Encision Inc. (OTCQB:ECIA), a medical device company owning ... in minimally invasive surgery, today announced financial results for ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $311 thousand, or $(0.04) per share, in the ...
(Date:7/29/2014)... , July 29, 2014   ... announced that it has taken an exclusive worldwide licence ... Ltd, a Durham University spin-out ... will pay an upfront fee, development and commercial milestone ... has also taken an option for additional exclusive licences ...
(Date:7/28/2014)... July 28, 2014  Dignity Health St. Mary,s ... the Get With The Guidelines®-Stroke Silver-Plus Quality Achievement ... by the American Heart Association/American Stroke Association for ... number four cause of death and a leading ... United States , according to the American ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 2Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 3Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 3
(Date:7/29/2014)... 2014 This month, Therapy Changes ... to a Successful, Balanced Career.” The guide is geared ... seeking guidance on creating a successful career. , ... focus, determination, and understanding your strengths and limits,” says ... guide will uncover the elements to creating balance in ...
(Date:7/29/2014)... 29, 2014 Premier Women’s Health ... Moon Township areas, has affiliated with Allegheny Health Network’s ... continue to deliver babies and perform surgical procedures at ... care will be referred to Allegheny Health Network’s ... be associated with West Penn Hospital and its highly ...
(Date:7/29/2014)... Regents Health Resources, a consulting firm ... health care industry veteran Daryl Demonbreun and former St. ... the company’s ambitious plans to grow into a full-service ... moving along at a steady pace for nearly 20 ... notch,” says Bob Maier, founder and chief executive officer ...
(Date:7/29/2014)... 2014 This Latest Guidebook for Conducting ... (2014 Edition) not only provided a comprehensive and thorough ... for imported drug registration but also introduced the practical ... guide you to use the Chinese trial venues to ... world step by step. , The audiences of this ...
(Date:7/29/2014)... (CA) method is in principle suitable to find out ... widely use it in health economic evaluations, some (primarily ... the result of a pilot project by the German ... Following the Analytic Hierarchy Process (AHP), CA is the ... experts. , Summarize outcome-specific results to an overall ...
Breaking Medicine News(10 mins):Health News:Therapy Changes Releases New Guide to Building a Successful Career 2Health News:Leading West Suburban OBGYN Practice, Premier Women’s Health, Joins Allegheny Health Network 2Health News:Leading West Suburban OBGYN Practice, Premier Women’s Health, Joins Allegheny Health Network 3Health News:Sferrella and Demonbruen Join Regents Health Resources 2Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 2Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 3Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 4Health News:Determine patient preferences by means of conjoint analysis 2Health News:Determine patient preferences by means of conjoint analysis 3Health News:Determine patient preferences by means of conjoint analysis 4
... may be an effective treatment for patients with a ... which was focused on the mechanism by which an ... important role because it suggests that changes in light ... inhibits mating of the C. neoformans -- a potentially ...
... risk of vertebral bone fractures in women with low bone ... 55 and 80 years with bone mineral density T scores ... women randomly received five milligrams of alendronate for two years ... placebo. ,The risk of vertebral fracture was significantly reduced ...
... and people without liver cancer found that diabetics are stand ... to the general population. ,After taking other factors into ... disease, researchers found diabetes nearly tripled the risk of liver ... factor for liver cancer, may be boosting the risk even ...
... be a treatment for life-threatening asthma (LTA) in children, according ... were treated with intravenous administration of sodium bicarbonate to reduce ... in LTA. , It was seen that in 17 ... was a decrease in blood carbon dioxide levels accompanied by ...
... the standard test to detect dementia so that it ... early. The test called National Institute //of Ageing's ... list (CWL) needs only ten minutes to administer. ... dementia as these stages often go undetected. They used ...
... as folate or a form of vitamin B. this vitamin if ... having a twin baby or to avoid //neural tube defect. A ... proof for this common belief. ,The study was conducted ... there are some countries were it is a common practice to ...
Cached Medicine News:
... Aplicare's saturated swabsticks are packaged in ... 4 inch swabstick is saturated with precisely ... The Gel Swabstick is saturated with a ... The gel is also approved for venipuncture ...
... BETADINE® Spray provides 5% ... pump spray. It delivers ... wounds too tender to ... and is indicated whenever ...
... that does not contain Alcohol. ... destroys over 99% of bacteria. ... of minor wounds, burns, cuts, ... personal utensils and tools. Prevents ...
BETADINE® Surgical Scrub is a microbicidal, sudsing cleanser that promptly kills most bacteria, fungi, viruses, protozoa and yeasts. It is indicated for hand hygiene, surgical hand-scrubbing, an...
Medicine Products: